In Re: Opana ER Antitrust Litigation
Garwin Gerstein & Fisher LLP was named co-lead class counsel on behalf of a class of direct purchasers of brand or generic Opana ER 5, 10, 20, 30, and/or 40 mg tablets. Defendants are (a) Endo Health Solutions Inc., Endo Pharmaceuticals Inc., and Penwest Pharmaceuticals Co. (collectively, “Endo”) and (b) Impax Laboratories, Inc. (“Impax”). Plaintiffs allege that Defendants violated the Sherman Act when Endo and its generic competitor, Impax, entered into an anticompetitive reverse payment settlement agreement delaying generic competition for Opana ER, thereby maintaining the price of Opana ER at supra-competitive levels, and overcharging plaintiffs and members of the class. Plaintiffs are seeking overcharge damages incurred by the class caused by Defendants’ misconduct.
Click document titles to open them.